Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Athira Pharma
(NASDAQ:ATHA)
Intraday
$2.57
0.01
[0.39%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$2.57
0.01
[0.39%]
Last update: 8:32AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Athira Pharma Stock (NASDAQ:ATHA)
Athira Pharma Stock (NASDAQ: ATHA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 27, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
17 hours ago
Friday, March 08, 2024
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference
Benzinga Newsdesk
-
Mar 8, 2024, 7:01AM
Thursday, February 08, 2024
Athira Pharma Announces Publication In Frontiers In Neuroscience Highlighting Therapeutic Potential Of ATH-1105 In Amyotrophic Lateral Sclerosis
Benzinga Newsdesk
-
Feb 8, 2024, 4:22PM
Monday, January 08, 2024
Athira Pharma Provides 2024 Clinical Pipeline Outlook; Topline Data From Phase 2/3 LIFT-AD Trial Of Fosgonimeton For Mild-to-moderate Alzheimer's Disease Expected In 2H Of 2024;
Benzinga Newsdesk
-
Jan 8, 2024, 8:23AM
Wednesday, January 03, 2024
Athira Pharma Has Completed Enrollment In The Phase 2/3 LIFT-AD Trial Of Fosgonimeton As A Potential Treatment For Mild-to-moderate Alzheimer's Disease; Topline data Is On Track For 2H Of 2024
Benzinga Newsdesk
-
Jan 3, 2024, 7:08AM
Tuesday, January 02, 2024
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Avi Kapoor
-
Jan 2, 2024, 6:40AM
Tuesday, December 12, 2023
Athira Pharma Announces Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Benzinga Newsdesk
-
Dec 12, 2023, 7:02AM
Tuesday, November 28, 2023
Athira Pharma Announced That A Symposium Presentation Highlighting Data From Preclinical Studies Of ATH-1105 For Amyotrophic Lateral Sclerosis Will Be Delivered At The Upcoming Motor Neurone Disease Association International Symposium
Benzinga Newsdesk
-
Nov 28, 2023, 7:16AM
Wednesday, November 15, 2023
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations And Neuroinflammation In Models Of Alzheimer's Disease
Benzinga Newsdesk
-
Nov 15, 2023, 8:18AM
Thursday, November 09, 2023
Athira Pharma Q3 EPS $(0.87) Misses $(0.81) Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 5:11PM
Thursday, October 05, 2023
Athira Pharma Presents Preclinical Data Further Supporting The Therapeutic Potential Of ATH-1105 In Amyotrophic Lateral Sclerosis
Benzinga Newsdesk
-
Oct 5, 2023, 4:32PM
Thursday, September 28, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 28, 2023, 2:32PM
Monday, September 11, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Sep 11, 2023, 1:38PM
Friday, September 08, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 8, 2023, 1:58PM
Thursday, September 07, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 7, 2023, 1:55PM
Monday, August 28, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Aug 28, 2023, 1:54PM
Friday, August 11, 2023
JMP Securities Maintains Outperform on Athira Pharma, Lowers Price Target to $19
Benzinga Newsdesk
-
Aug 11, 2023, 7:43AM
Thursday, August 10, 2023
Athira Pharma Q2 EPS $(0.78) Beats $(0.79) Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 5:06PM
Monday, July 17, 2023
Athira Pharma Highlights Presentation Of Alzheimer's Data
Benzinga Newsdesk
-
Jul 17, 2023, 7:09AM
Monday, June 12, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Jun 12, 2023, 9:06AM
Wednesday, June 07, 2023
Chief Medical Officer at Athira Pharma Exercises Options Worth $26K
Benzinga Insights
-
Jun 7, 2023, 11:00AM
Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Lisa Levin
-
Jun 7, 2023, 8:32AM
Tuesday, May 23, 2023
Director at Athira Pharma Acquires Company Stock Options Worth 20,900 Shares
Benzinga Insights
-
May 23, 2023, 11:03AM
Athira Pharma Board Member Awarded $63K Worth of Stock Options
Benzinga Insights
-
May 23, 2023, 11:03AM
Athira Pharma Director Awarded $63K Worth of Stock Options
Benzinga Insights
-
May 23, 2023, 11:03AM
Monday, May 15, 2023
Mizuho Maintains Buy on Athira Pharma, Lowers Price Target to $5
Benzinga Newsdesk
-
May 15, 2023, 6:56AM
Friday, May 12, 2023
FDA Rejects ImmunityBio's Bladder Cancer Therapy Filing
Zacks
-
May 12, 2023, 4:41PM
Tuesday, April 25, 2023
Athira Pharma Presents New Clinical, Preclinical Data At American Academy Of Neurology 2023 Annual Meeting
Michael Horton
-
Apr 25, 2023, 4:27PM
Monday, April 03, 2023
$1.7M Bet On Glatfelter? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Lisa Levin
-
Apr 3, 2023, 8:25AM
Thursday, March 30, 2023
BTIG Maintains Buy on Athira Pharma, Lowers Price Target to $10
Benzinga Newsdesk
-
Mar 30, 2023, 10:24AM
Tuesday, March 28, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Mar 28, 2023, 1:43PM
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential Of Fosgonimeton For Alzheimer's And Parkinson's Diseases At AD/PD 2023 International Conference
Happy Mohamed
-
Mar 28, 2023, 1:13AM
Friday, March 24, 2023
JMP Securities Reiterates Market Outperform on Athira Pharma, Maintains $20 Price Target
Benzinga Newsdesk
-
Mar 24, 2023, 8:03AM
Thursday, March 23, 2023
Athira Pharma FY22 EPS $(2.53)
Michael Horton
-
Mar 23, 2023, 4:31PM
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Mar 23, 2023, 1:11PM
Monday, March 20, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Mar 20, 2023, 1:29PM
Thursday, March 09, 2023
Athira Pharma Filed U.S. Patent Application # 20230070758: Methods Of Treating Alzheimer's Disease
Charles Gross
-
Mar 9, 2023, 5:38AM
Tuesday, January 03, 2023
4 Penny Stocks Insiders Are Buying: Athira Pharma, Great Elm Group And More
Lisa Levin
-
Jan 3, 2023, 9:10AM
Wednesday, December 07, 2022
Beachbody, Athira Pharma And This Penny Stock Insiders Are Aggressively Buying
Lisa Levin
-
Dec 7, 2022, 6:30AM
Monday, December 05, 2022
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential Of ATH-1105 In ALS At The 33rd International Symposium On ALS/MND
Benzinga Newsdesk
-
Dec 5, 2022, 7:34AM
Tuesday, November 29, 2022
Athira Pharma Highlights Therapeutic Potential Of Fosgonimeton In Presentation Of Additional Biomarker Data In Mild-To-Moderate Alzheimer's Disease Patients From ACT-AD Phase 2 Study At CTAD Conference
Benzinga Newsdesk
-
Nov 29, 2022, 11:01AM
Friday, November 18, 2022
Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying
Lisa Levin
-
Nov 18, 2022, 11:55AM
Thursday, November 10, 2022
Athira Pharma Q3 EPS $(0.53) Down From $(0.42) YoY
Benzinga Newsdesk
-
Nov 10, 2022, 4:55PM
Monday, October 17, 2022
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study Of Fosgonimeton In Mild-to-Moderate Alzheimer's Patients Following Independent, Unblinded Interim Analysis
Benzinga Newsdesk
-
Oct 17, 2022, 7:02AM
Tuesday, September 06, 2022
Athira Outlines Possible Comeback For Alzheimer's Candidate
Vandana Singh
-
Sep 6, 2022, 3:22PM
Athira Pharma Provides Update On Plans For Ongoing LIFT-AD Clinical Study Of Fosgonimeton In Mild-To-Moderate Alzheimer's Patients; Adapting Study To Focus On The Evaluation Of Fosgonimeton Monotherapy
Bill Haddad
-
Sep 6, 2022, 7:03AM
Monday, August 15, 2022
Athira Pharma: Q2 Earnings Insights
Benzinga Insights
-
Aug 15, 2022, 7:21PM
Athira Pharma Q2 EPS $(0.65) Down From $(0.38) YoY
Benzinga Newsdesk
-
Aug 15, 2022, 4:20PM
Monday, July 25, 2022
Athira Pharma To Present Clinical and Preclinical Data At Alzheimer's Association International Conference 2022
Benzinga Newsdesk
-
Jul 25, 2022, 7:04AM
Thursday, July 07, 2022
Athira Pharma shares are trading higher after Mizuho initiated coverage on the stock with a Buy rating and a $6 price target.
Michael Horton
-
Jul 7, 2022, 2:13PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch